Study S002035

Efficacy and Durability of Glucagon Like Peptide 1 Receptor Agonists (GLP-1 RA)/Thiazolidinedione Versus Basal Bolus Insulin Therapy in Poorly Controlled Type 2 Diabetic Patients (T2DM) Patients on Sulfonylurea Plus Metformin

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02887625
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: UNKNOWN
Enrollment: 410
Start: 2015-02
Primary completion: 2017-05
Lead sponsor: Dr. Muhammad Abdulghani
Conditions: Type 2 Diabetes
Interventions: DRUG:Pioglitazone plus exenatide; DRUG:insulin glargine and insulin aspart
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

HbA1c [3 years]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0036730	Central and peripheral neurodegeneration in diabetes and dementia Georgios Ponirakis, e-space (Manchester Metropolitan University)	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT02887625
R0026120	Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Abdul-Ghani M, Diabetes care	2017	Randomized trial	PMID 28096223 DOI	cites ClinicalTrials.gov:NCT02887625; registry reference DERIVED:28096223